Bratha

Part 3.0 — Cognitive Performance Compounds

17 min read

This is Part 3 of 4 in the Cognitive Enhancement Series (the active software stack). The full path:

  • Part 1 — Foundation (2 sub-articles):
  • Part 2 — The Base:
    • Part 2.0: The Behavioral Base (the 90% that comes before any compound, and where it ladders in your life)
  • Part 3 — Pharmacology (2 sub-articles):
  • Part 4 — Application (4 sub-articles):

Table of Contents

Read the gate before the compounds

This article gives doses and brand names because, like the Sleep series, vague hand-waving helps no one; these are documented clinical and OTC figures. But several compounds here are prescription-only or controlled substances in Malaysia (the amphetamines, methylphenidate, modafinil, and the cholinesterase inhibitors all sit under prescription or poison control), and the research chemicals have no long-term human safety data. Doses are reference points for harm reduction, not encouragement. If you skipped Part 2.0, go back: adding any of this on a broken base is how you get the side effects and none of the benefit.

Before you read this as a shopping list

The temptation is to skim for the strongest compound and order it. Resist. The entire value of the architecture is that you now add a compound to fix a specific failing lever identified by your measurements, not to “get smarter” in general.

The decision flow is always the same:

  1. Which lever is failing? Can’t start (Executive Function)? Can’t retain (Memory)? Getting stuck and overwhelmed (Flexibility)? Your data from Part 1.0 tells you.
  2. Have you exhausted the behavioural fix? Most “Executive Function” problems are dopamine-baseline problems Part 2.0 solves for free.
  3. Start at the lowest tier that addresses it. You don’t open with the prescription stimulant any more than you open a fitness journey with Trenbolone.
  4. Change one thing, then measure. The single-variable rule from Part 1.0 is the only way to know if it worked.

The three-tier system

To keep this structured instead of “everywhere,” every compound is classified into one of three tiers, the same logic an enhanced athlete uses to rank gear from pharmaceutical staples to grey-market research chemicals.

The tiers

  • Tier 1: Clinical Essentials (Prescription / Gold Standard). Prescription medications with mountains of human safety data and predictable, heavy mechanisms. Powerful, regulated, and carrying real medical risk. Controlled or prescription-only in Malaysia.
  • Tier 2: Bio-Identical & Premium OTC. Natural precursors, bio-identical compounds, and highly bioavailable supplements that work with the body’s own pathways. High safety margin, no prescription, widely available. This is where you should live.
  • Tier 3: Experimental & Synthetic (Research Chemicals). Synthetic nootropics, peptides, and grey-market “smart drugs.” Often highly specific and genuinely interesting, but lacking the decades of human safety data that make Tier 1 and 2 trustworthy. Tier 3 is for people who accept they are the long-term study.

The honest default for almost everyone is: build the base (Part 2.0), live in Tier 2, and reserve Tier 1 for genuine high-stakes, maximum-output days under proper supervision. Tier 3 is optional and entered with eyes open.

Pillar 1: Executive Function & Drive (Dopamine / Norepinephrine)

The lever for starting and grinding: it drives your task latency toward zero. These work, broadly, by leaving more dopamine and norepinephrine active in the synapse, locking you onto a task.

Tier 1: Clinical Essentials

  • Methylphenidate (Ritalin, Concerta): a dopamine/norepinephrine reuptake inhibitor. Direct, intense, reliable focus. Standard ADHD dosing runs ~10–20 mg per immediate-release dose (extended-release formulations differ). Heavy cardiovascular tax: elevated heart rate and blood pressure.
  • Amphetamine salts (Adderall) / lisdexamfetamine (Vyvanse): these don’t just block reuptake, they force release of dopamine and norepinephrine. Maximum drive, and maximum cost: the highest cardiovascular load, the worst comedowns, and real dependence potential.
  • Modafinil (Provigil) / Armodafinil (Nuvigil): eugeroics (wakefulness-promoting agents). Typical clinical dose 100–200 mg modafinil (≈150 mg armodafinil) once in the morning. Sharp wakefulness with markedly less peripheral anxiety, cardiovascular strain, and crash than the classical stimulants, and a good safety profile in trials.1

The Modafinil reality check (this matters for your framework)

Modafinil is sold around entrepreneur circles as the premier “wealth” stimulant. The evidence is more sober than the hype. Its effects are strong in sleep-deprived people but modest in well-rested ones: meta-analysis in healthy, non-sleep-deprived subjects finds mainly an attention benefit, with little to no effect on memory or motivation.1 Translation: ==Modafinil is far better at rescuing a depleted brain than at super-charging a fresh one.== Its single best, most evidence-backed use is exactly the one its label describes (defending performance when you’re under-slept), which is a reason to fix sleep first, not a substitute for it.

The Adderall tax on your other pillars

Amphetamines are excellent for Executive Function and terrible for the other two pillars and for your hardware. They crash your Peaceful pillar (anxiety, irritable comedowns) and load your Healthy one (heart rate, blood pressure), overlapping directly with the cardiovascular risks you already monitor on cycle. For an enhanced lifter, stacking amphetamine cardiovascular load on top of gear is a genuinely bad idea. If you need Tier 1 drive, the eugeroics are the lower-tax choice.

Tier 2: Premium OTC

  • L-Tyrosine / N-Acetyl-L-Tyrosine (NALT): the direct amino-acid precursor to dopamine. 500–2,000 mg. It doesn’t force a dopamine surge; it restocks the raw material, which is why it shines for replenishing depleted dopamine after heavy output or under acute stress, rather than as an acute “kick.” A cornerstone of the natural stack in Part 4.1.
  • Caffeine: the universal base stimulant. 100–200 mg. Works by blocking adenosine (the fatigue signal), with downstream dopaminergic effects. Always pair it with L-theanine (see Pillar 3) to keep the focus and drop the jitter: the most reliable, cheapest cognitive combo that exists.
  • Rhodiola Rosea (adaptogen): 100–250 mg of a 3% rosavins / 1% salidroside extract. A mild MAO-inhibitor that slows the breakdown of dopamine and norepinephrine, plus an HPA-axis adaptogen that blunts stress-fatigue, so it reads as clean anti-fatigue drive rather than a stimulant kick.2 It stacks heavily with caffeine and with Saffron (Pillar 3), so use it as a swing weapon for low-sleep, high-stress days rather than daily (the timing logic is in Part 4.1).

Tier 3: Experimental

  • Bromantane: an atypical compound that up-regulates the enzymes (tyrosine hydroxylase) that synthesise dopamine, rather than forcing a dump, giving a smoother, more “actogenic” profile. Limited but interesting human data, mostly Russian.
  • Phenylpiracetam: a phenyl-modified piracetam with potent stimulant-like, dopaminergic activity. Notably, it builds tolerance fast and is on WADA’s banned list, relevant if you ever compete in anything tested.

Pillar 2: Memory & Processing (Acetylcholine, fuel vs brake)

The lever for learning, retaining, and synthesising. The key distinction from Part 1.0: you can supply the fuel (raw material for acetylcholine) or release the brake (stop its breakdown), and they are not interchangeable.

Tier 1: Clinical Essentials (the brake-release)

  • Donepezil (Aricept) / Galantamine (Razadyne): acetylcholinesterase inhibitors that block the enzyme which destroys acetylcholine, keeping your learning chemistry active far longer. Powerful, and the reason they’re approved for Alzheimer’s. But acetylcholine also runs the parasympathetic nervous system and the gut, so chronic use brings nausea, muscle cramps, vivid dreams and sleep disruption, and a heavy, “wired-cholinergic” feeling. Using an Alzheimer's drug for a healthy brain is the definition of a sledgehammer for a finishing nail. Reserve-only, if at all.

Tier 2: Premium OTC (the fuel, plus an OTC brake)

  • Alpha-GPC: the most bioavailable choline donor; crosses the blood-brain barrier easily to serve as raw fuel for acetylcholine. Common dose 300–600 mg active.

    The alpha-GPC stroke signal, worth flagging ~46% higher 10-year stroke risk, dose-dependently, the proposed mechanism being that the liberated choline is converted by gut bacteria to TMAO, which promotes atherosclerosis.1 This is observational (association, not proven causation) and in an older population, but it's a real signal, and it matters more for you specifically, because an enhanced lifter is already managing cardiovascular and lipid load on cycle. The pragmatic move: don't run high-dose alpha-GPC daily for years, and consider CDP-choline as the lower-TMAO alternative.

    A large 2021 South Korean cohort study (>12 million adults, 50+) found alpha-GPC use associated with a

  • CDP-Choline (Citicoline, “Cognizin”): 250–500 mg. Dual-action: it provides choline fuel and up-regulates uridine to support brain-cell membranes (which ties directly into the uridine story in Part 3.1). Lower TMAO burden than alpha-GPC, which makes it the more conservative choline source for a lifter.
  • Huperzine-A: 100–200 mcg. A botanical acetylcholinesterase inhibitor, effectively an OTC version of the Tier 1 brake. It has a long half-life, so it accumulates; daily use without breaks can cause headaches, muscle twitches, and that over-cholinergic heaviness. Cycle it (e.g. a few days on, a few off), don't run it continuously.
  • ALCAR (Acetyl-L-Carnitine): 500–2,000 mg. Supplies an acetyl group that feeds both acetylcholine synthesis and mitochondrial energy, so it doubles as a memory input and a mental-fatigue buffer. Sits alongside the choline donors above, and pairs with creatine on the energy side (Part 3.1).
  • Bacopa Monnieri: ~300 mg standardised to 50% bacosides. A slow-acting memory builder (it improves recall and attention speed, with benefits accruing over weeks rather than hours) that is also mildly neuroprotective and antioxidant, so it straddles into the Preservation bucket.2 The patience tax is real: judge it at 4–6 weeks, not on day one.

The fuel-and-brake overload trap

Running a strong fuel (alpha-GPC) and a brake (Huperzine-A, or worse, Donepezil) hard at the same time can tip you into acetylcholine overload: depressive mood dips, jaw clenching, muscle stiffness, and a distinct “heavy” brain fog. More choline is not more memory past a point; it’s another inverted-U. This is also why piling DMAE on top of alpha-GPC is redundant and risky, covered in Part 4.1.

Tier 3: Experimental

  • PRL-8-53: a synthetic compound with a single small 1970s study suggesting dramatically improved short-term word retention. Intriguing, essentially un-replicated, and with no modern safety data. The honest label: a curiosity, not a tool.

Pillar 3: Flexibility & State Control (GABA / Serotonin)

The lever for task-switching, lateral thinking, pivoting, and not panicking under load. The full mechanism (how calm produces flexibility, why over-stimulation creates rigid tunnel vision, and the whole signal-to-noise / inverted-U story) is the subject of Part 1.1 and won’t be repeated here.

The one line you need before the compounds: ==raising drive raises the noise as well as the signal, so flexibility comes from quieting the noise (GABA/serotonin), not from adding more stimulant.== GABA (the brain’s main inhibitory brake) and serotonin (mood stability, impulse control) act as a lateral-inhibition system that selectively quiets non-essential chatter so the signal can move. So when you feel driven but stuck and overwhelmed, this is the pillar to reach for, never another eugeroic. Here are the compounds that pull it.

Tier 1: Clinical Essentials

  • Buspirone (Buspar): a serotonin (5-HT1A) partial agonist that reduces anxiety without sedation or dependence, unusually clean for an anxiolytic. Typical dose 5–10 mg, 2–3× daily; takes a couple of weeks to work.

    Benzodiazepines are deliberately excluded will make you calm, but they degrade cognitive performance (memory, processing), cause tolerance and severe dependence, and have no place in a performance stack. They are the cognitive equivalent of the Z-drugs in the Sleep series: a sedation trap, not a tool. Omitted on purpose.

    Alprazolam (Xanax), diazepam, and the rest hit GABA-A hard and

Tier 2: Premium OTC

  • L-Theanine: 100–200 mg. Crosses the blood-brain barrier, boosts alpha brain waves and GABA, and takes the edge off stimulants perfectly. The golden pairing is 2:1 theanine-to-caffeine (e.g. 200 mg theanine / 100 mg caffeine) for clean, jitter-free focus. The single highest-value Pillar-3 compound and a backbone of Part 4.1.
  • Ashwagandha (KSM-66): ~300–600 mg. An adaptogen that down-regulates cortisol and stabilises mood under chronic stress. Best evidence of the herbal anxiolytics. (Note for the enhanced lifter: ashwagandha can nudge thyroid and hormonal markers, worth knowing if you’re tracking a panel.)
  • 5-HTP: the direct precursor to serotonin. Effective for mood but use with real care: daily use can dysregulate the serotonin system, it shouldn’t be combined with any serotonergic medication (SSRIs or MAOIs, given the serotonin-syndrome risk), and it’s best intermittent, not a daily driver.
  • Saffron (standardised, 0.3% safranal): ~30 mg. Behaves like a mild reuptake inhibitor for serotonin and dopamine, holding them in the synapse longer for a smooth, un-stimulated mood lift: the calm-confidence end of state control, with small RCTs showing antidepressant-comparable effects in mild-to-moderate low mood.2 (It interacts with serotonergic drugs, so the same serotonin-syndrome caution as 5-HTP applies.)

Tier 3: Experimental

  • Phenibut / Baclofen: synthetic GABA-B agonists. Profound calm and “flow-state” confidence, and a genuinely dangerous dependence and withdrawal profile.

    Phenibut is a trap never more than 1–2× per week, and many people can't hold that line. For a project about sustainable high output, a compound you can use only rarely and that punishes daily use with dependence is a poor fit. Listed for completeness, recommended against.

    Phenibut withdrawal is comparable to benzodiazepine withdrawal and tolerance builds within days. The only safe rule is

  • Selank: a synthetic peptide (a Russian analog of the anxiolytic tuftsin) that modulates inflammatory signalling (IL-6) and stabilises serotonin/GABA balance under stress, without sedation or dependence. Usually a nasal spray. Interesting and well-tolerated in the (limited, mostly Russian) literature; no long-term Western safety data.

Nicotine: the multi-receptor wildcard

Nicotine straddles two pillars and deserves its own section. Detached entirely from smoking and vaping and treated as a precise pharmaceutical (gum, lozenge, or patch), it’s one of the fastest, most reliable acute focus tools available.3

  • Where it sits: Executive Function and Memory & Processing. It binds nicotinic acetylcholine receptors, which triggers a downstream release of dopamine, norepinephrine, and acetylcholine at once: the focus of a stimulant plus the processing edge of a cholinergic. Tier 2 by access (pharmaceutical-grade NRT is OTC), but with Tier-1-level dependence risk.
  • The habit-stamping use: a controlled spike timed to the start of a target task gives a clean dopamine hit that helps stamp the behaviour, the legitimate technique from Part 2.0.
  • The neuroprotective claim, fact-checked: nicotine does show neuroprotective effects in animal models, and epidemiology has long noted smokers have lower Parkinson’s incidence.3 But the human trial evidence (e.g. nicotine patches in Parkinson’s) has been weak-to-disappointing, and the smoking epidemiology is heavily confounded. Treat "nicotine is neuroprotective" as a plausible mechanism, not an established benefit you should chase.

The dependence ceiling is the whole story

Nicotine’s downside is not exotic toxicity; it’s that it is profoundly habit-forming and down-regulates fast. Keep it small and occasional: 1–2 mg lozenges or gum, not all day, not every day. The moment it becomes an idle default rather than a deliberate tool, it’s a liability: you’ve recreated the cheap-dopamine baseline problem Part 2.0 worked to drain, in pharmaceutical form. The cautious default is to use it as a swing weapon, not a daily driver, though there’s a reasoned case for a strictly context-gated daily habit-anchor, weighed honestly in Part 4.2.

The Performance stack at a glance

PillarTier 1 (Clinical)Tier 2 (Premium OTC)Tier 3 (Experimental)
Executive Function (dopamine/norepi)Modafinil/Armodafinil · Methylphenidate · AmphetaminesL-Tyrosine/NALT · Caffeine (+theanine) · RhodiolaBromantane · Phenylpiracetam
Memory & Processing (acetylcholine)Donepezil · GalantamineCDP-Choline · Alpha-GPC* · Huperzine-A · ALCAR · BacopaPRL-8-53
Flexibility & State (GABA/serotonin)BuspironeL-Theanine · Ashwagandha (KSM-66) · 5-HTP · SaffronSelank · (Phenibut, avoid)
Multi-receptor—Nicotine (NRT, tactical only)—

*Alpha-GPC carries the cardiovascular/stroke caveat above; CDP-choline is the more conservative choline source.

The decision principle, restated

Diagnose the failing lever, then start at the lowest tier that addresses it. Most people, most of the time, should be building a Tier-2 stack (Part 4.1), reaching into Tier 1 only for genuine high-stakes days, and entering Tier 3 only with eyes fully open. The strongest compound for the wrong lever is worse than the right compound at the lowest dose.

Part 3 Takeaways

Key concepts to internalise

  • Three tiers: Clinical (prescription, powerful, regulated) · Premium OTC (where you should live) · Experimental (you’re the long-term study). Start low.
  • Executive Function: stimulants/eugeroics work by keeping dopamine/norepi active. Modafinil is great for the depleted brain, only modest for the rested one: fix sleep first. Amphetamines carry a heavy cardiovascular and Peace tax, bad to stack on gear.
  • Memory: distinguish fuel (choline donors; prefer CDP-choline, since alpha-GPC has a real stroke/TMAO signal) from the brake (cholinesterase inhibitors; Huperzine-A OTC, cycle it, and Donepezil is a sledgehammer). Don’t overload both: cholinergic overload is real.
  • Flexibility: calm creates flexibility by improving signal-to-noise. When “driven but stuck,” add GABA/serotonin support (L-theanine, ashwagandha), not more stimulant. Benzos and phenibut are dependence traps, excluded on purpose.
  • Nicotine is a fast, multi-receptor focus and habit-stamping tool, and a serious dependence risk. Tactical, 1–2 mg, never daily. Its neuroprotection is plausible-not-proven.
  • Always: diagnose the lever, change one variable, measure (Part 1.0).

Up next

That’s the software you deploy. Part 3.1 — Neural Preservation covers the hardware you protect: BDNF/NGF and neurogenesis, glutamate regulation and neuroprotection, the neurosteroid base (and the TRT-brain-fog fix), plus where systemic biomarkers like hs-CRP actually fit.

Disclaimer

This article is educational and is not medical advice. Methylphenidate, amphetamines, modafinil/armodafinil, donepezil, galantamine, and buspirone are prescription medications; several are controlled substances in Malaysia, and obtaining or using them without a prescription is illegal and unsafe. Stimulants are dangerous in people with cardiovascular disease, arrhythmia, or uncontrolled blood pressure (directly relevant to enhanced athletes). Research chemicals (Tier 3) lack long-term human safety data entirely. Nothing here is a recommendation to obtain or use any scheduled drug; consult a qualified doctor.

Sources & references

Footnotes

  1. Repantis, D. et al. (2010), “Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review,” Pharmacological Research 62(3):187–206; and Battleday, R.M. & Brem, A.-K. (2015), “Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review,” European Neuropsychopharmacology 25(11):1865–1881. Effects are robust under sleep deprivation but modest in well-rested subjects, with the most consistent benefit on attention/executive function on complex tasks and little effect on memory or motivation; generally favourable side-effect profile. PubMed 26381811. ↩ ↩2

  2. The natural-stack botanicals. Bacopa: Kongkeaw, C. et al. (2014), Journal of Ethnopharmacology 151(1):528–535 (improves memory free recall and attention speed; ~300 mg/day standardised, effects building over weeks). Rhodiola: Ishaque, S. et al. (2012), BMC Complementary and Alternative Medicine 12:70 (anti-fatigue, with the caveat that trial quality is inconsistent). Saffron: Hausenblas, H.A. et al. (2013), “Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials,” Journal of Integrative Medicine 11(6):377–383 (saffron comparable to antidepressants for mild-to-moderate depression in small RCTs). ↩ ↩2 ↩3

  3. Quik, M., Perez, X.A. & Bordia, T. (2012), “Nicotine as a potential neuroprotective agent for Parkinson’s disease,” Movement Disorders 27(8):947–957. nAChR activation is neuroprotective in parkinsonian animal models; epidemiology links smoking to lower PD incidence, but human therapeutic trials have been limited/equivocal and the epidemiology is confounded. PMC3685410. On nicotine’s acute cognitive (attention/memory) effects in humans: Heishman, S.J. et al. (2010), Psychopharmacology 210:453–469. ↩ ↩2

Graph View

Backlinks